---
title: "New Stock Dark Market | ALEBUND-B initially rose 76.99%, with a paper profit of HKD 1,740 for one lot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290935893.md"
description: "Hong Kong stock \"the first stock of innovative kidney disease drugs\" ALEBUND-B will be listed on the Hong Kong Stock Exchange on June 29 (Monday). Today, in the dark market, as of the time of writing, dark market trading shows its price at HKD 40, an increase of 76.99% compared to the offering price of HKD 22.60. Each lot is 100 shares, and excluding handling fees, each lot has a paper profit of HKD 1,740"
datetime: "2026-06-26T08:36:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290935893.md)
  - [en](https://longbridge.com/en/news/290935893.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290935893.md)
---

# New Stock Dark Market | ALEBUND-B initially rose 76.99%, with a paper profit of HKD 1,740 for one lot

According to Zhitong Finance APP, Hong Kong stock "the first stock of innovative kidney disease drugs" ALEBUND-B (09637) will be listed on the Hong Kong Stock Exchange on June 29 (Monday). Today, in the dark market, as of the time of publication, dark market trading shows a price of HKD 40, an increase of 76.99% compared to the offering price of HKD 22.60. Each lot is 100 shares, and excluding handling fees, each lot has a paper profit of HKD 1,740

### Related Stocks

- [09637.HK](https://longbridge.com/en/quote/09637.HK.md)

## Related News & Research

- [Biotech Firms Push Weight-Loss and AI Pipelines Amid Buyback Wave](https://longbridge.com/en/news/291029476.md)
- [Beijing Biostar Wins Shareholder Backing for Capital Mandates and Governance Changes at AGM](https://longbridge.com/en/news/290979536.md)
- [Beijing Biostar Pharmaceuticals files directors list with Hong Kong exchange](https://longbridge.com/en/news/290974298.md)
- [China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds](https://longbridge.com/en/news/290965367.md)
- [Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules](https://longbridge.com/en/news/290642767.md)